The National Institutes of Mental Health (NIMH) has granted $7.3m to researchers at the Feinstein Institutes for Medical Research to support their efforts to provide improved treatment for schizophrenia.

The schizophrenia clinical research study is led by Dr John Kane and Dr Delbert Robinson under the name ‘Early-phase Schizophrenia: Practice-based Research to Improve Treatment Outcomes (ESPRITO).’

Schizophrenia is a serious mental illness and brain disabling chronic disorder that impacts a persons ability to control their emotions.

It is also defined by disorganised thinking and abnormal social behaviour, as well as disturbances in perceptions.

Feinstein Institutes Institute of Behavioral Science professor and schizophrenia researcher Dr John Kane said: “We are excited to build off of our previous work to develop improved and more uniform services for early intervention in schizophrenia.

Feinstein Institutes associate professor Dr Robinson said: “With this new clinical research, we aim to improve treatment strategies and medication adherence and help patients continue to receive the care they need to get back to their everyday lives.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

With the help of ESPRITO programme, 11 clinics across four states will provide the NAVIGATE model of coordinated speciality care. The application of standard measurement and data gathering will help in providing enhanced treatment quality, consistency, and response.

The NIMH-funded clinical research will enable researchers to address hurdles in early-phase intervention and reduce hospitalisations, preventing patients from discontinuing the clinical study phase and improving overall outcomes.

Feinstein Institutes president and CEO Kevin Tracey said: “NIH support of early-phase schizophrenia research is in the national interest.

“Doctors Kane and Robinson’s research offers hope for patients to achieve a better quality of life.”